Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Vaxcyte Inc PCVX

Healthcare Biotechnology
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent... see more

Recent & Breaking News (NDAQ:PCVX)

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

GlobeNewswire December 8, 2025

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

GlobeNewswire November 4, 2025

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

GlobeNewswire September 30, 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

GlobeNewswire September 3, 2025

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

GlobeNewswire August 6, 2025

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 7, 2025

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

GlobeNewswire May 1, 2025

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

GlobeNewswire March 31, 2025

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

GlobeNewswire March 30, 2025

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire February 25, 2025

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Newsfile February 17, 2025

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

GlobeNewswire February 12, 2025

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

GlobeNewswire February 5, 2025

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire January 30, 2025

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

PR Newswire January 7, 2025

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

GlobeNewswire December 3, 2024

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Newsfile November 20, 2024

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

GlobeNewswire November 12, 2024

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 5, 2024

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 11, 2024

Podcasts